Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2005
10/27/2005WO2005099699A1 Combination of (s)-amlodipine and a beta-blocker, and methods for reducing hypertension
10/27/2005WO2005099698A1 STABILIZED 4-AMINO-5-CHLORO-N-[(1R,3r,5S)-8-METHYL-8- AZABICYCLO[3.2.1]OCT-3-YL]-2-[1-METHYLBUT-2-YNYLOXY]-BENZAMIDE CONTAINING COMPOSITION
10/27/2005WO2005099697A1 Use of phencynonate hydrochloride for treating or alleviating epilepsy
10/27/2005WO2005099696A1 Medicine comprising combination of acetylcholine esterase inhibitor and 5-substituted 3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivative
10/27/2005WO2005099695A1 Drug delivery systems for the prevention and treatment of vascular diseases
10/27/2005WO2005099694A1 Combination of a heterocyclic compound and an antioxidant and use thereof for treating obesity
10/27/2005WO2005099693A2 Methods and materials for assessing prostate cancer therapies and compounds
10/27/2005WO2005099692A1 Efficacious composition of a benzimidazole, an avermectin and praziquantel and related methods of use
10/27/2005WO2005099691A1 Composition for treating elevated intraocular pressure
10/27/2005WO2005099690A1 Use of a pyrazole derivative for producing medicaments that are useful in preventing and treating chronic bronchitis and chronic obstructive bronchopneumopathy
10/27/2005WO2005099689A1 Topical delivery of phthalocyanines
10/27/2005WO2005099688A2 Cyclic compounds
10/27/2005WO2005099687A2 Analogs of salinosporamide a
10/27/2005WO2005099686A1 Edible composition having effects of promoting the production and release of calcitonin gene-related peptide
10/27/2005WO2005099685A1 Liquid external preparation containing sodium cromoglycate
10/27/2005WO2005099684A1 Benzofuranyl derivatives useful for the treatment of cardiac arrhythmia
10/27/2005WO2005099683A1 Antibacterial agent whose active ingredint is methyl paraoxybenzoate and composition for external application containing the same
10/27/2005WO2005099682A1 Preparations for external use
10/27/2005WO2005099681A1 Tablet containing branched chain amino acid and process for producing the same
10/27/2005WO2005099680A2 Use of treprostinil to treat neuropathic diabetic foot ulcers
10/27/2005WO2005099679A1 New double salts of (-)-hydroxycitric acid and a process for preparing the same
10/27/2005WO2005099678A1 Pharmaceutical compositions and method of using levodopa and carbidopa
10/27/2005WO2005099677A1 Bazedoxifene acetate solid dispersion formulations
10/27/2005WO2005099673A1 Polycylic thiazoles as potassium ion channel modulators
10/27/2005WO2005099671A2 Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
10/27/2005WO2005099666A2 Delayed release formulations of 6-mercaptopurine
10/27/2005WO2005099665A2 Imroved formulations of 6-mercaptopurine
10/27/2005WO2005099486A1 Process for preparing lagerstroemia speciosa l. extract
10/27/2005WO2005099485A1 Health food, process for producing the same and dried matter or extract
10/27/2005WO2005099479A1 Methods and compositions for reducing oxidative stress in an animlal
10/27/2005WO2005099478A1 Method and compositions for reducing oxidative stress in an animal
10/27/2005WO2005099455A1 Dietary supplements containing extracts of cinnamon and methods of using same to enhance creatine transport
10/27/2005WO2005099453A1 Antiparasitical agents and methods for treating, preventing and controlling external parasites in animals
10/27/2005WO2005099367A2 Systems and methods for improving image-guided tissue ablation
10/27/2005WO2005090992A3 Mptens as modifiers of the pten pathway and methods of use
10/27/2005WO2005087763A9 Diphenylmethyl compounds useful as muscarinic receptor antagonists
10/27/2005WO2005084129A3 Structured triglycerides and emulsions comprising same
10/27/2005WO2005082356A3 Use of beta-lapachone for the treatment of lung cancer
10/27/2005WO2005079773A3 Combination of an nmda receptor antagonist and an anti-epileptic drug for the treatment of epilepsy and other cns disorders
10/27/2005WO2005079770A8 Use of a compound modulating at least one receiver selected in a group comprising an interleukin 8 type b receptor and pacap-1 receptor for preparing a pharmaceutical composition for rosacea treatment
10/27/2005WO2005079164A3 5α-REDUCTASE INHIBITORS
10/27/2005WO2005076888A3 Anti-cancer therapies
10/27/2005WO2005074642A3 Chemical compounds
10/27/2005WO2005072740A3 Anorectic compounds
10/27/2005WO2005072719A8 Medicinal acidic cannabinoids
10/27/2005WO2005072204A3 6,11-3c-bicyclic 8a-azalide derivatives
10/27/2005WO2005070932A3 Substituted heterocyclic compounds and methods of use
10/27/2005WO2005066115A8 Disubstituted chalcone oximes having rarϝ retinoid receptor antagonist activity
10/27/2005WO2005065685A8 Controlled release pharmaceutical composition comprising an acid-insoluble polymer and a bioadhesive polymer
10/27/2005WO2005065645A3 Donepezil formulations
10/27/2005WO2005063300A3 Cosmetic or pharmaceutical preparations containing nucleic acid sequences forming a superstructure
10/27/2005WO2005061491A3 Aralkyl and aralkylidene heterocyclic lactams with affinity for 5-ht1 receptors
10/27/2005WO2005061483A3 Modulators of peripheral 5-ht receptors
10/27/2005WO2005058248A3 A method of treating hiv infection in atazanavir resistant patients using a combination of atazanavir and another protease inhibitor
10/27/2005WO2005051353A3 Pharmaceutical formulations comprising voriconazole
10/27/2005WO2005048912A3 Methods and compositions for the treatment of helicobacter pylori-associated diseases using endoperoxide bridge-containing compounds
10/27/2005WO2005046567B1 Synergistic formulation of antioxidants and antimycobacterial agents: a method of making the same
10/27/2005WO2005044988A3 21-heterocyclic-4-azasteroid derivatives as androgen receptor modulators
10/27/2005WO2005044823A3 Polymorphous forms of rifaximin as antibiotics
10/27/2005WO2005044178A3 Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
10/27/2005WO2005041861A3 Anhydrous silver dihydrogen citrate compositions
10/27/2005WO2005040338A3 Constrained alkaloid immunogens and antibodies and uses thereof
10/27/2005WO2005034972A3 Use of pharmaceutical compositions containing evening primrose oil for the treatment of xerostomia
10/27/2005WO2005034848A3 Inhibitors of cathepsin s
10/27/2005WO2005034728A3 Colon cleansing composition and method
10/27/2005WO2005033311A3 Methods for modulating neuronal responses using inhibitors of ampa receptor endocytosis
10/27/2005WO2005030144A3 Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
10/27/2005WO2005027824A3 Cyclic bis-compounds clearing malformed proteins
10/27/2005WO2005021515B1 Inhibitors of phosphodiesterase type-iv
10/27/2005WO2005007825A3 Modulation of aminopeptidase n expression
10/27/2005WO2005007103A3 Use of parthenolide derivatives as antileukemic and cytotoxic agents
10/27/2005WO2004110255A3 Antineoplastic agents targeted via glut transporters
10/27/2005WO2004100867A3 Method and kit for regulation of microvascular tone
10/27/2005WO2004093826A3 Compositions of cyclooxygenase-2 selective inhibitors and 5-ht1b/1d agonists for the treatment and prevention of migraine
10/27/2005WO2004093821A3 Treatment of anthrax infection using inhibitors of lethal factor protease activity
10/27/2005WO2004078940A8 USE OF ANTISENSE OLIGONUCLEOTIDES OR siRNA TO SUPPRESS EXPRESSION OF eIF-5A1
10/27/2005WO2004075854A3 Microbicidal compositions and method of use
10/27/2005WO2004073648A3 Composition and methods for inhibiting cell survival
10/27/2005WO2004064760A3 Aptamer therapeutics useful in ocular pharmacotherapy
10/27/2005WO2004063348A3 Vesicant treatment with phenyl-thiophene type vitamin d receptor modulators
10/27/2005WO2004058704A8 Quinazolinones as potassium channel modulators
10/27/2005WO2004048330A8 N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them
10/27/2005WO2004016213A3 Combinatorial libraries of autoinducer analogs, autoinducer agonists and antagonists, and methods of use thereof
10/27/2005WO2004002490A3 Piperidine compounds as antibacterials
10/27/2005WO2003072595A3 Methods and products based on oligomerization of stress proteins
10/27/2005US20050240182 Supplemental spine fixation device and method
10/27/2005US20050240166 Implantable device, formulation and method for anti-psychotic therapy using risperidone
10/27/2005US20050240062 protecting 3,5-DIhydroxybenzaldehyde with diisopropylethylamine/N,N-/ and silyl chloride, reacting 3,5-di(tert-butyldimethylsilyloxy)-benzaldehyde product with 4-methoxybenzyltriphenylphosphonium bromide to obtain 3,5-di(tert-butyldimethylsilyloxy)-4'-methoxy-stilbene, deprotecting and separating
10/27/2005US20050240035 polymerase inhibitors such as -1-(5-Cyano-pyridin-2-yl)-3-(1,1a,2,7b-tetrahydro-cyclopropa[c]chromene-1-yl)-urea, used as antiviral agents
10/27/2005US20050240027 Carvedilol phosphate salts and/or solvates thereof, corresponding compositions and/or methods of treatment
10/27/2005US20050240023 Cathepsin cysteine protease inhibitors
10/27/2005US20050240021 Fused heterobicyclo substituted phenyl metabotropic glutamate-5 modulators
10/27/2005US20050240017 5-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-5,11-dihydro-6-oxa-12-thia-dibenzo[a,f]azulen-2-ol; 13-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-7,13-dihydro-12-oxa-benzo[4,5]cyclohepta[1,2-a]naphthalen-3-ol or derivatives or salts; for alleviating symptoms of estrogen deprivation, including bone loss
10/27/2005US20050240006 Cytoplasmic region with more than 107 or less than 104 amino acids, a transmembrance region, and an extracellular region; nucleic acids and antibodies; diagnosing hematopoietic cell malignancy or autoimmune disease
10/27/2005US20050239906 Use of resveratrol for the preparation of a medicament useful for the treatment of influenza virus infections
10/27/2005US20050239905 Smooth muscle peristole inhibitor
10/27/2005US20050239904 Polycosanols from Ericerus pela wax
10/27/2005US20050239903 Such as 4-(tert-butyl)-2-(2-hydroxyphenyl)phenol; for use mouthwashes, antiperspirants
10/27/2005US20050239902 Phenoxyalkycarboxylic acid derivatives in the treatment of inflammatory diseases
10/27/2005US20050239901 Drugs; therapy for kidney diseases; removal of bile acid; gastrointestinal disorders; core-shell polymer
1 ... 4487 4488 4489 4490 4491 4492 4493 4494 4495 4496 4497 4498 4499 4500 4501 4502 4503 4504 4505 4506 4507 ... 7860